A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

NCT07205315 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia (B-ALL)
Chronic Lymphocytic Leukemia (CLL)
B-cell Non-Hodgkin's Lymphoma (B-NHL)
Autoimmune Hemolytic Anemia (AIHA)

Interventions

BIOLOGICAL: GT801 Injection

Sponsor

Grit Biotechnology

Collaborators

[object Object]
[object Object]
[object Object]